Everything below concerns heptapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-05. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity are confirmed with reversed-phase high-performance liquid chromatography, typically monitored at 214 nanometres where the peptide bond absorbs. Mass spectrometry, either electrospray or MALDI-TOF, verifies molecular mass against the theoretical value and detects truncation or adduct formation. Amino acid analysis and peptide mapping provide additional confirmation when required. The most frequently reported impurities are deletion sequences from incomplete coupling, methionine sulfoxide from oxidation, and dimeric species formed through non-covalent aggregation. Impurity profiles depend strongly on the synthesis and purification route chosen by the producer.
Published research has focused mainly on neurological and cognitive endpoints in animal models, with proposed mechanisms involving brain-derived neurotrophic factor and related signalling pathways. A substantial share of the human data originates from a limited number of research groups, and independent replication in other countries remains sparse. Regulatory status reflects that distribution: the peptide is registered as a medicine in Russia and appears in some neighbouring markets, while elsewhere it is handled as a research chemical without approved therapeutic labelling. Questions about dose-response relationships, long-term effects, and comparability across studies are still open.
Reported pharmacological work centers on neurotrophic signaling, including changes in BDNF and NGF expression in hippocampal tissue in animal models. Human data come largely from studies conducted in Russia, and how well those results generalize to other populations remains an open question. Regulatory status differs sharply by jurisdiction: Semax is a registered prescription medicine in Russia, while it holds no approved marketing status in the United States or the European Union. Outside such jurisdictions it is generally handled as a research chemical, which affects both documentation and quality expectations.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. It was developed as a fragment analog of adrenocorticotropic hormone, modeled specifically on the ACTH(4-10) region. The first four residues reproduce that fragment, while a Pro-Gly-Pro tripeptide is appended at the C-terminus. Work on the compound originated in Russia, where it entered clinical use as an intranasal preparation. Its sequence places it among short regulatory peptides studied for effects on the central nervous system rather than on the adrenal axis.
The C-terminal Pro-Gly-Pro extension is not incidental. Proline-rich tails are known to resist several common peptidases, and the published literature attributes the longer half-life of Semax, relative to unmodified ACTH fragments, to this feature. The modification also removes the melanocyte-stimulating and corticosteroidogenic activity that characterizes longer ACTH-derived sequences. Because the molecule is small and hydrophilic, it is typically formulated as an aqueous solution for intranasal or parenteral delivery. Acetylation or amidation at the termini appears in closely related research peptides and shifts the mass by a fixed increment.
| Property | Value | Notes |
|---|---|---|
| Purity assay | RP-HPLC, UV 214 nm | Typical research grade 95 percent or higher |
| Mass confirmation | ESI-MS or MALDI-TOF | Compared with theoretical value |
| Main degradation route | Methionine oxidation | Sulfoxide formation in solution |
| Powder storage | -20 °C, desiccated | Amber vial, minimal headspace |
| Working solution | Sterile water or saline | Prepare fresh; avoid repeated thawing |
Verification of a supplied batch generally combines a certificate of analysis with independent testing, because certificates are self-reported documents. A typical package includes a chromatographic trace, a mass spectrum, and a stated water or counter-ion content. Batch-to-batch consistency matters more than a single purity figure when results are compared across experiments. No single mandatory standard governs research-grade peptide release, so laboratories are expected to define their own acceptance criteria. Residual trifluoroacetate from purification is a frequently overlooked counter-ion.
Lyophilized material is chemically stable for extended periods when kept dry, cold, and protected from light. The powder is hygroscopic, so vials should be warmed to room temperature before opening to reduce condensation on the contents. Once dissolved, the peptide is far less stable because peptide bonds are susceptible to hydrolysis and the methionine residue can oxidize. Solutions are typically aliquoted and held at 2-8 °C for short intervals or frozen for longer ones, and repeated freeze-thaw cycles should be avoided.
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.
Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.
3.D.1 The H+ or Na+-translocating NADH Dehydrogenase ("complex I") family 3.D.2 The Proton-translocating Transhydrogenase (PTH) Family 3.D.3 The Proton-translocating Quinol:Cytochrome c Reductase) Superfamily 3.D.4 Proton-translocating Cytochrome Oxidase (COX) Superfamily 3.D.5 The Na+-translocating NADH:Quinone Dehydrogenase (Na-NDH or NQR) Family 3.D.6 The Putative Ion (H+ or Na+)-translocating NADH:Ferredoxin Oxidoreductase (NFO or RNF) Family 3.D.7 The H2:Heterodisulfide Oxidoreductase (HHO) Family 3.D.8 The Na+- or H+-Pumping Formyl Methanofuran Dehydrogenase (FMF-DH) Family 3.D.9 The H+-translocating F420H2 Dehydrogenase (F420H2DH) Family 3.D.10 The Prokaryotic Succinate Dehydrogenase (SDH) Family
However, brief mitochondrial permeability transition pore openings play an essential physiological role in maintaining healthy mitochondrial homeostasis. Ciclosporin can induce a remission of proteinuria caused by such diseases as MCD and FSGS. Ciclosporin blocks the calcineurin-mediated dephosphorylation of synaptopodin, a regulator of Rho GTPases in podocytes, thereby preserving the phosphorylation-dependent synaptopodin-14-3-3 beta interaction. Preservation of this interaction, in turn, protects synaptopodin from cathepsin L-mediated degradation. Altogether, the antiproteinuric effect of Ciclosporin results, at least in part, from the maintenance of synaptopodin protein abundance in podocytes, which, in turn, is sufficient to maintain the integrity of the glomerular filtration barrier and to safeguard against proteinuria.
Acral nevus (melanocytic nevus of acral skin, melanocytic nevus with intraepidermal ascent of cells) Amelanotic blue nevus (hypomelanotic blue nevus) Balloon cell nevus Bannayan–Riley–Ruvalcaba syndrome Becker's nevus (Becker's melanosis, Becker's pigmentary hamartoma, nevoid melanosis, pigmented hairy epidermal nevus) Benign melanocytic nevus (banal nevus, common acquired melanocytic nevus, mole, nevocellular nevus, nevocytic nevus) Blue nevus (blue neuronevus, dermal melanocytoma, nevus bleu) Blue nevus of Jadassohn–Tièche (common blue nevus, nevus ceruleus) Carney complex (LAMB syndrome, NAME syndrome) Cellular blue nevus Centrofacial lentiginosis Congenital melanocytic nevus Deep penetrating nevus Dysplastic nevus (atypical mole, atypical nevus, B-K mole, Clark's nevus, dysplastic melanocytic nevus, nevus with architectural disorder) Dysplastic nevus syndrome (B-K mole syndrome, familial atypical multiple mole–melanoma syndrome, familial melanoma syndrome) Ephelis (freckle) Epithelioid blue nevus Generalized lentiginosis Giant pigmented nevus (bathing trunk nevus, congenital nevomelanocytic nevus, garment nevus, giant hairy nevus, nevus pigmentosus et pilosus) Halo nevus (leukoderma acquisitum centrifugum, perinevoid vitiligo, Sutton nevus) Hori's nevus (acquired bilateral nevus of Ota-like macules) Inherited patterned lentiginosis in black persons Ink spot lentigo (sunburn lentigo) Laugier–Hunziker syndrome Lentigo simplex (simple lentigo) Malignant blue nevus Medium-sized congenital nevocytic nevus Melanoacanthoma Melanocytic tumors of uncertain malignant potential Moynahan syndrome Mucosal lentigines (labial and penile and vulvar melanosis, melanotic macules) Nevus of Ito (nevus fuscoceruleus acromiodeltoideus) Nevus of Ota (congenital melanosis bulbi, melanosis bulborum and aberrant dermal melanocytosis, nevus fuscoceruleus ophthalmomaxillaris, oculodermal melanocytosis, oculomucodermal melanocytosis) Nevus spilus (speckled lentiginous nevus, zosteriform lentiginous nevus) Partial unilateral lentiginosis (segmental lentiginosis) Peutz–Jeghers syndrome Pigmented spindle cell nevus (pigmented spindle cell tumor of Reed, pigmented variant of Spitz nevus) Pseudomelanoma (recurrent melanocytic nevus, recurrent nevus) PUVA lentigines Small-sized congenital nevocytic nevus Spitz nevus (benign juvenile melanoma, epithelioid and spindle cell nevus, Spitz's juvenile melanoma) Solar lentigo (lentigo senilis, liver spot, old age spot, senile freckle)
=== Testosterone === Men with low levels of testosterone can experience ED. Taking testosterone may help maintain an erection. Males with type 2 diabetes are twice as likely to have lower levels of testosterone, and are three times more likely to experience ED than non-diabetic men.
The novel is permeated by poetological, often self-deprecating reflections, which are discussed in the form of possible objections Jutta or the editor might raise against the novel—and which culminate in an emphatic endorsement of the power of literature.
Sources: en.wikipedia.org
=== Indirect size measurement of intact complexes === Sedimentation-velocity analytical ultracentrifugation (measures the translational diffusion constant) Dynamic light scattering (measures the translational diffusion constant) Pulsed-gradient protein nuclear magnetic resonance (measures the translational diffusion constant) Fluorescence polarization (measures the rotational diffusion constant) Dielectric relaxation (measures the rotational diffusion constant) Dual polarisation interferometry (measures the size and the density of the complex) Methods that measure the mass or volume under unfolding conditions (such as MALDI-TOF mass spectrometry and SDS-PAGE) are generally not useful, since non-native conditions usually cause the complex to dissociate into monomers. However, these may sometimes be applicable; for example, the experimenter may apply SDS-PAGE after first treating the intact complex with chemical cross-link reagents.
Another study of the PfSPZ vaccine was published in December 2022, reporting vaccine efficacy at up to 48% at 6 months follow up, and up to 46% efficacy at 18 months. Recent field studies have evaluated PfSPZ Vaccine in malaria-experienced African adults. A randomized, double-blind, placebo-controlled trial in Burkina Faso tested a three-dose intravenous regimen and reported vaccine efficacy of up to 48% at 6 months and 46% at 18 months against naturally acquired Plasmodium falciparum infection. The vaccine was well tolerated and immunogenic in this population. Additional studies in Equatorial Guinea examined multi-dose priming regimens of PfSPZ Vaccine followed by controlled human malaria infection (CHMI). Several schedules were found to be safe and capable of inducing significant protection against homologous challenge. By 2022 more than twenty clinical trials of PfSPZ-based products had been completed or were ongoing across Africa, Europe and the United States. PfSPZ Vaccine has also been evaluated in women of childbearing age and in participants who later became pregnant. Two randomized, double-blind, placebo-controlled trials in Mali investigated vaccination following presumptive antimalarial treatment. Across two transmission seasons, vaccine efficacy against Plasmodium falciparum parasitaemia in women of childbearing age ranged from 41% to 61%, depending on dose and year of follow-up. Among participants who conceived after vaccination, the vaccine was safe for mothers and infants and reduced the incidence of malaria parasitaemia during pregnancy.
In 1983, financier Marc Rich was accused of violating the act by trading in Iranian oil during the Iran hostage crisis. He was one of many people pardoned by President Bill Clinton in his last days in office. On August 23, 2006, Javed Iqbal was arrested through the U.S. Department of the Treasury with a charge of conspiracy to violate the IEEPA for airing material produced by al-Manar (The Beacon) in New York City during the 2006 Israel-Lebanon conflict. On December 16, 2009, it was announced that the U.S. Department of Justice reached a settlement with Credit Suisse over accusations that the bank assisted residents of IEEPA sanctioned countries to wire money in violation of the Act from 1995 to 2006. The settlement resulted in Credit Suisse forfeiting $536 million. On July 16, 2020, a UAE-based firm, Essentra FZE Company Limited, admitted of conspiring to violate the International Emergency Economic Powers Act (IEEPA) and defying the United States sanctions on North Korea. The firm also agreed to pay a fine of $665,112 to the United States Department of Justice.
Some women complain of a "small penis" when the trim procedure is performed, owing to the un-addressed clitoral hood tissue and completely removed (amputated) labia minor. Most plastic surgeons do not perform this procedure, and instead favor the extended wedge approach, which is technically more demanding, but produces a more natural result and is able to create a natural and proportioned appearance to the vulva. Reconstructive procedures are often required after the trim (amputation) labiaplasty.
== History == Remote Medical International is headquartered in Seattle, Washington, USA with employees based all over the globe. The company was founded by Andrew Cull, a remote area paramedic in 2003. Inc. Magazine has named RMI three times as one of the 500 fastest growing companies in the US. In 2011, Remote Medical International was listed in the "Top Twenty Places to Work" in Seattle. RMI has approximately 100 employees, most of which are medical professionals. In 2013, Remote Medical International received an $8 million investment from "Seattle-based Columbia Pacific Management, which already owns 23 hospitals in India, Malaysia, Vietnam and Indonesia through a related company, Columbia Asia." RMI partners with Columbia Asia and uses its hospital as a base of operations in Asia.
Sources: en.wikipedia.org
One of these strains was used for creation of replication deficient SeV85AB construct that is lacking fusion protein (F) but has inserted sequence encoding immunodominant antigen of Mycobacterium tuberculosis. The safety and immunogenicity of this construct was tested in animal models. This construct can be easily transformed into the construct that encodes S-protein of SARS-CoV-2. In Russia, State Research Center of Virology and Biotechnology VECTOR is in developing stage of vaccine against COVID-19 using Moscow strain of Sendai virus as a vector backbone. In Japan researchers have developed two intranasal vaccine candidates against SARS-CoV-2. One design utilizes a modified Sendai virus (SeV) as a vector to deliver the SARS-CoV-2 spike protein's receptor binding domain (RBD) directly to the respiratory tract. In pre-clinical studies, mice received the vaccine intranasally. Mice demonstrated elevated levels of antibodies specific to the SARS-CoV-2 S-RBD (IgM, IgG, IgA) in both their blood serum and bronchoalveolar lavage fluid, lasting up to 12 weeks. Another design uses a similar F-gene lacking SeV vector but different SARS-CoV-2 antigens. Instead of the S-protein, the vaccine design used SARS-CoV-2 nucleocapsid (N), membrane (M), and envelope (E) proteins as immunogens. The study found strong CD8+ T cell responses against these antigens, suggesting intranasal vaccination can trigger immune cells (CD8+ T cells) that target the virus and help control SARS-CoV-2 infection.
Relevant to the latter activity, a later study showed that this inhibitory effect was due to the ability of 12-oxo-HT to act as a partial antagonist of the thromboxane receptor: 12-oxo-HT blocks TXA2 binding to its receptor and thereby the responses of platelets and possibly other tissues to TXA2 as well as agents that depend on stimulating TXA2 production for their activity. Thus, 12-HHT forms simultaneously with, and by stimulating PGI2 production, inhibits TXA2-mediated platelet activation responses while 12-oxo-HT blocks TXA2 receptor binding to reduce not only TXA2-induced thrombosis and blood clotting but possibly also vasospasm and other actions of TXA2. In this view, thromboxane synthase leads to the production of a broadly active arachidonic acid metabolite, TXA2, plus two other arachidonic acid metabolites, 12-HHT and 12-oxo-HT, that serve indirectly to stimulate PGI2 production or directly as a receptor antagonist to moderate TXA2's action, respectively. This strategy may be essential for limiting the deleterious thrombotic and vasospastic activities of TXA2.
=== Human === In humans, ADH exists in multiple forms as a dimer and is encoded by at least seven genes. Among the five classes (I-V) of alcohol dehydrogenase, the hepatic forms that are used primarily in humans are class 1. Class 1 consists of α, β, and γ subunits that are encoded by the genes ADH1A, ADH1B, and ADH1C. The enzyme is present at high levels in the liver and the lining of the stomach. It catalyzes the oxidation of ethanol to acetaldehyde (ethanal):
A recombinant fusion protein is a protein created through genetic engineering of a fusion gene. This typically involves removing the stop codon from a cDNA sequence coding for the first protein, then appending the cDNA sequence of the second protein in frame through ligation or overlap extension PCR. That DNA sequence will then be expressed by a cell as a single protein. The protein can be engineered to include the full sequence of both original proteins, or only a portion of either. If the two entities are proteins, often linker (or "spacer") peptides are also added, which make it more likely that the proteins fold independently and behave as expected. Especially in the case where the linkers enable protein purification, linkers in protein or peptide fusions are sometimes engineered with cleavage sites for proteases or chemical agents that enable the liberation of the two separate proteins. This technique is often used for identification and purification of proteins, by fusing a GST protein, FLAG peptide, or a hexa-his peptide (6xHis-tag), which can be isolated using affinity chromatography with nickel or cobalt resins. Di- or multimeric chimeric proteins can be manufactured through genetic engineering by fusion to the original proteins of peptide domains that induce artificial protein di- or multimerization (e.g., streptavidin or leucine zippers). Fusion proteins can also be manufactured with toxins or antibodies attached to them in order to study disease development.
== Education == Valko completed her Master of Pharmacy from Semmelweis University in 1997, followed by a PhD in Pharmaceutical Chemistry and Pharmacology from the same institution in 1979. Later in 1996, she obtained a DSc degree in Drug Discovery from Hungarian Academy of Sciences.
Sources: en.wikipedia.org
Reversed-phase HPLC gives the main purity figure, most often with UV detection near 214 nanometres. Mass spectrometry then confirms the molecular mass. Together the two methods distinguish a correct sequence from a closely related impurity.
The main chemical risks are methionine oxidation and backbone hydrolysis in solution. Moisture and repeated temperature cycling accelerate both processes. Dry powder held cold and desiccated is considerably more stable than any reconstituted preparation.
It holds a medicine registration in Russia, where it has been used clinically for decades. In most other countries it is treated as a research chemical. That split explains the uneven distribution of clinical literature.
The sequence is Met-Glu-His-Phe-Pro-Gly-Pro, a seven-residue peptide. The first four residues correspond to the ACTH(4-10) fragment, and Pro-Gly-Pro is added at the C-terminus. N-acetylated versions also appear in the literature and differ in mass.